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Abstract
Background and Aims: A visual analogue score (VAS),
based on application of a visual analogue scale, has been
widely used to assess pruritus in clinical studies of patients
with cholestatic liver disease. A VAS is a numerical score of
the severity of the perception of pruritus, and, hence, is inherently subjective. The objective of this study was to assess
the reliability of a VAS as an index of pruritus in cholestatic
patients. Methods: In 8 patients with chronic pruritus due to
primary biliary cholangitis, values for a VAS of pruritus were
compared with corresponding measurements of scratching
activity, which were generated by a monitoring system specifically designed to quantitate this activity. The relationship
between individual values for the VAS and corresponding
values for scratching activity during a specific interval immediately preceding the recording of the VAS was examined
by determining the Spearman’s rank correlation coefficient.
Results: The mean Spearman’s rank correlation coefficient
between individual values for the VAS and corresponding
mean values for scratching activity was 0.072; the range of
these coefficients was −0.04 to 0.26. A VAS of pruritus is an
unreliable index of scratching activity, and, hence, of the
pathophysiological process responsible for the pruritus of
cholestasis. Conclusion: It is concluded that the use of a
VAS as a primary quantitative endpoint in trials of the efficacy
of potential therapies for the pruritus of cholestasis may be
inappropriate.
Citation of this article: Bergasa NV, Jones EA. Assessment
of the visual analogue score in the evaluation of the pruritus
of cholestasis. J Clin Transl Hepatol 2017;5(3):203–207. doi:
10.14218/JCTH.2017.00001.

Introduction
The clinical syndrome of cholestasis is a complication of many
hepatobiliary diseases. The syndrome arises as a consequence of impaired hepatocellular secretion of bile from any
cause. It is characterized by an accumulation in plasma of
substances that are normally secreted into bile, such as
Keywords: Pruritus; Cholestasis; Visual analogue score; Scratching activity;
Primary biliary cholangitis; Quantitative efficacy endpoint.
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bilirubin, bile acids and cholesterol.1,2 A distressing symptom
in many patients with cholestasis is pruritus. This symptom
may be severe and intractable, and associated with sleep
deprivation and suicidal ideations. Relief from this symptom
is often difficult to achieve. Indeed, intractable pruritus of
cholestasis may be an indication for liver transplantation.3
A notable feature of this form of pruritus, in contrast to many
others, is that it is not readily relieved by scratching. The
pathogenesis of the pruritus of cholestasis is unknown.4–6
In accordance with the basic principles of clinical science, it
has long been recognized that progress in studying factors
that relieve or exacerbate this form of pruritus would be
facilitated by applying an appropriate objective quantitative
method to its assessment. Such an approach would be likely
to provide insights into the pathogenesis of the pruritus and,
when used as an endpoint in clinical trials, would provide a
means for assessing the efficacy of potential therapies. In this
context, a visual analogue score (VAS) of pruritus, based on
the application of a visual analogue scale (Fig. 1), appears to
have been widely accepted as a method of assessing pruritus
in clinical studies of chronic cholestasis.7–13 However, the reliability and objectivity of the numerical data generated from
the inherently subjective marks made by cholestatic patients
on visual analogue scales do not seem to have been critically
evaluated.
As scratching is a consequence of pruritus, an alternative
method of assessing the severity of the pruritus of cholestasis,
which is independent of any subjective input from patients,
is to measure directly the intensity of scratching activity.
In this study, the relationship between measurements of the
perception of pruritus, as assessed from a VAS, and scratching
activity, as assessed by applying a monitoring system specifically designed to measure this activity (Fig. 2),14 was evaluated in patients with pruritus due to the chronic cholestatic
disease, primary biliary cirrhosis. The results have implications for the optimal design of clinical trials of potential therapies for pruritus.
Methods
Patients
Eight female patients with chronic pruritus secondary to the
chronic cholestatic disease, primary biliary cholangitis, formerly known as primary biliary cirrhosis, were studied. The
patients had been participants of a pilot controlled trial of
naloxone infusions for the pruritus of cholestasis.15 The
design was a single-blind, placebo controlled study of naloxone infusions administered in a non-predetermined order.15
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Descriptions of pruritus
Fig. 1. A visual analogue scale consisting of a 10-cm horizontal line. The
origin of the line on the left side is designated “no itch” and the end of the line on
the right side is designated “worst itching ever”. To indicate the severity of itch, a
patient is requested to make a mark on the scale that corresponds to the relative
severity of itch currently being experienced. This mark is made with a pen or
pencil. The visual analogue score (VAS) is the number of centimeters to the
nearest millimeter between the origin of the scale on the left side and the mark on
the scale made by the patient.15

In none of the patients had the pruritus been relieved satisfactorily by scratching or by conventional medications that
are commonly prescribed for this type of pruritus, such as
orally administered resins (e.g., cholestyramine, colestipol),
antihistamines or phenobarbital.1,6 Their ages ranged from
46 to 62 years.
For each patient, results of routine serum biochemical
tests were indicative of cholestasis over a period of at least
2 years, and a needle biopsy of the liver revealed histological
features characteristic of primary biliary cholangitis.16 The
serum of all but one of the patients was positive for antibodies
to mitochondria. Each patient gave informed consent to participate in the study. All antipruritic medications were discontinued at least 5 days before the onset of the study. Before
entering the study, each patient was observed to scratch with
their fingernails at frequent intervals.

The patients’ descriptions of their perception of pruritus varied
substantially. For example, the sensation was described as
“biting” by one patient, “pins and needles” by another, and
as a burning and intolerable feeling sometimes like “taking
the skin off” by another. In most patients the pruritus was
generalized, but in one it was localized to the chest, face and
scalp. One patient was self-conscious about her itching and
was concerned that other people might think that her scratching indicated that her condition was contagious; she stated
that her itching was worse when she went home from work
and that it was less of a problem when she was working and
distracted by specific activities. In one patient the pruritus
tended to be more severe at the time of menstruation; she
had an unsatisfactory marital relationship and her perception
of severe pruritus was sometimes rapidly and dramatically
relieved by a change of environment (e.g., emergency
admission to hospital). Another patient also had an unsatisfactory marital situation and she was skeptical that she would
derive any benefit from medical therapy for her pruritus,
feeling that only liver transplantation would alleviate the
symptom. These descriptions highlight the subjectivity of
the perception of the pruritus of cholestasis and the heterogeneous nature of its impact on different patients.

Fig. 2. Block diagram of the scratching activity monitoring system. The system consists of a vibration (scratch) transducer, an FM transmitter and receiver, a custombuilt signal processor and a personal computer. The vibration transducer is taped to the middle fingernail of the dominant hand. The transducer consists of a square piece of
piezoelectric film, 28-mm thick, metalized on both sides with silver ink. It is connected by wire to a transmitter that is attached to the adjacent arm by a Velcro cuff. The
transducer converts the strain produced by vibrations of the fingernail as it traverses the skin in the act of scratching into an electrical voltage. The electrical signal is
transmitted across the room where it is received, processed and logged by a computer. Frequencies associated with vibrations of the scratching fingernail were found to be
between 30 and 1000 Hz, whereas those associated with gross body movements were <30 Hz. The device is programmed to exclude signals with frequencies of <30 Hz, so
that scratching activity independent of arm or hand movements was recorded as a scratching activity index, with units of counts per unit time.13 The average scratching
activity for consecutive 15-minute intervals was recorded.
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VASs

Statistical analysis

Every 4 waking-hours, patients were asked to record the
average severity of their pruritus during the preceding 4-hour
period by making a mark with a pen or pencil on a visual
analogue scale. The scale consisted of a 10-cm horizontal
line, with 0-cm point (beginning of scale on the left side)
being designated as representing no itching and the 10-cm
point (end of scale on the right side) representing worst ever
itching (Fig. 1).17 A VAS is the number of centimeters, to the
nearest millimeter, between 0 cm and the point on the scale
where the patient made a mark.

Recordings of scratching activity during 4-hour periods
immediately prior to individual determinations of a VAS
were analyzed. The first VAS after waking was not included
in the analysis because of the possible effects of sleep on the
perception of itch. The relationship between individual values
for the VAS and corresponding values for scratching activity
during a specific interval immediately preceding the recording
of the VAS was examined by determining the Spearman’s
rank correlation coefficient (rs). Specifically, the set of VAS
values recorded by each patient was correlated with the corresponding set of values for scratching activity recorded
during the immediately preceding 15-minute period. Similar
correlations were also determined between VAS values and
mean values for scratching activity recorded during the
immediately preceding 30-, 60-, 120- and 240-minute intervals. Four to 11 sets of these comparisons were made for each
patient.

Index of scratching activity
An objective numerical index of scratching activity was generated by applying a monitoring system specifically designed
to measure this activity.14 Scratching activity was continuously recorded for the duration of the study, which was conducted in the in-patient research unit. Briefly, the system
consisted of a vibration (scratch) transducer, an FM transmitter and receiver, a custom-built signal processor and a personal computer (Fig. 2). The vibration transducer was taped
to the middle fingernail of the dominant hand; this fingernail
was not cut during the study. The transducer consisted of a
square piece of piezoelectric film, 28-mm thick, metalized on
both sides with silver ink. It was connected by wire to a transmitter that was attached to the adjacent arm by a Velcro cuff.
The transducer converted the strain produced by vibrations of
the fingernail as it traversed the skin in the act of scratching
into an electrical voltage.
The electrical signal was transmitted across the room,
where it was received, processed and logged by a computer.
Frequencies associated with vibrations of the scratching
fingernail were found to be between 30 and 1000 Hz,
whereas those associated with gross body movements were
<30 Hz. The device was programmed to exclude signals with
frequencies of <30 Hz, so that scratching activity independent of arm or hand movements was recorded as a scratching
activity index, with units of counts per unit time.14 The
average scratching activity for consecutive 15-minute intervals was recorded. For this study, scratching activity was
recorded continuously for 2 to 4 successive 24-hour periods.

Results
Spearman’s rank correlation coefficients between individual
values for the VAS and mean values for scratching activity
recorded during five different time intervals immediately
preceding the recording of the VAS, varied between 0.04
and 0.26 (Table 1). The overall mean correlation coefficient
was 0.072. Thus, in this study population with primary biliary
cholangitis, the severity of the perception of pruritus, as
assessed by a VAS, did not correlate with an objective quantitative index of scratching activity.
Discussion
Pruritus, or itching, is a major complication of cholestasis. Itch
is defined as the need to scratch and, hence, is intrinsically
subjective. As itch is a perception, it cannot be measured
directly. Itch has long been assessed subjectively by the use
of questionnaires and descriptive terms, such as mild, moderate and severe. It has also been assessed by determination
of a VAS, which enables the perception of itch to be represented by a numerical value, and, hence, gives the impression
that the severity of pruritus has been quantitated. Whether
such numbers represent an adequate or meaningful index
of pruritus has not been rigorously evaluated. Nevertheless,

Table 1. Spearman’s rank correlation coefficients between individual values for the visual analogue score (VAS) and mean values for scratching activity
recorded over 15, 30, 60, 120 and 240 minutes prior to the time point at which the visual analogue scale, from which the VAS was calculated, was
marked

Patient number

Number of VASs per patient

0–15’

0–30’

0–60’

0–120’

0–240’

1

4

−0.80

−0.80

−0.80

−0.80

−0.20

2

11

−0.20

−0.18

0.14

−0.01

−0.01

3

4

0.80

0.40

0.40

0.20

1.00

4

8

−0.01

0.07

−0.10

0.16

0.02

5

6

−0.44

−0.14

0.54

0.37

0.43

6

9

0.10

0.13

0.08

0.44

0.24

7

10

0.19

0.10

−0.12

0.01

0.12

8

10

0.14

0.69

0.46

0.63

0.46

−0.04

0.03

0.08

0.13

0.26

Average correlation coefficient
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determination of a VAS appears to be a well-established
research method for assessing pruritus in patients with
cholestasis.7–13 VAS has also been extensively applied in psychology and other medical disciplines, in which it has been
used to assess other specific symptoms, such as pain.17–19
However, an important issue is whether a VAS constitutes a
sufficiently reliable index of the severity of pruritus for its
application to be useful in clinical studies of cholestatic
patients.
In this context, it is probably worth carefully reconsidering
potential problems with interpreting a VAS that were highlighted in a landmark critical review by McCormack et al.17
Issues of concern include the following: (i) There tends to
be a tri-modal distribution of data points with clusters at the
midpoint and extremes of the visual analogue scale; (ii) Interpatient variability in marking the scales is evident; (iii) An
ability to transform a complex subjective experience into a
visual-spatial display, which involves perceptual judgement
and accuracy, is required; (iv) A variety of factors contribute
to respondent error, such as age, ability to think abstractly,
mental organization, and perceptual skills; (v) It is necessary
to examine how scales were marked on previous occasions;
and (vi) Early use of the maximal value precludes subsequent
accurate scoring of a greater perception.17
A VAS is, therefore, affected by inter-individual variations
in the ability of patients to integrate the perception of itch
over time and to translate the outcome of this process into a
visual-spatial score. The conceptualization of such a score is
also subject to inter-patient differences.17 In addition,
marking a visual analogue scale is subject to changes due
to hand and hand preferences,20 and the act of making a
mark on a horizontal line, such as a visual analogue scale,
can be influenced by sex.21 Thus, a variety of factors may
potentially contribute to uncertainty concerning the validity
of assessments of perceptions obtained by marking a visual
analogue scale.17 Nevertheless, VAS has been utilized extensively as an endpoint in clinical trials designed to determine
the efficacy of potential therapies for the pruritus of cholestasis.7–13 The discipline of clinical science requires that an
endpoint in a therapeutic trial be, not only relevant, but also
quantitative and objective. The question arises whether a VAS
meets these requirements in trials of potential therapies for
the pruritus of cholestasis.
To address this issue, it is necessary to compare values of a
VAS with objective measurements of another variable that
directly reflects the pathophysiology of the pruritus of cholestasis. As scratching can be defined as the behavioral consequence of pruritus, quantitative data on scratching activity,
which are independent of any subjective input from patients,
may fulfil this requirement. The first serious attempt to
measure scratching activity in pruritic patients was reported
over three decades ago, when a device was developed for
measuring limb movements in patients with pruritic skin
disorders.22 Subsequently, a more sophisticated apparatus
was designed to measure limb movements of patients with
pruritus due to chronic cholestasis.23 The development of
such an apparatus reflected the need for objective quantitative data in clinical studies of this syndrome. The major deficiency of these original methods was that measurements of
limb movements record activities other than scratching activity. This problem was subsequently overcome by developing
the well-tolerated device used in this study, which measures
scratching activity independent of hand or limb movements.14
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The validity of the scratching activity monitoring system
used in this study has been verified by demonstrating a close
concordance between its output (numerical values of a
scratching activity index or the intensity of an audio-signal
proportional to these values) and independent direct observations and video recordings of scratching activity by the
fingernail bearing the transducer. In particular, counts were
not recorded by the device during gross movements of the
relevant hand that were not associated with an interaction
between fingernails and the skin or during scratching activity
by the hand that did not bear the transducer.14 This monitoring system enables the behavioral consequence of the pruritus of cholestasis to be detected and measured irrespective of
whether patients complain of pruritus or perceive its sensation. Thus, in contrast to the sensation of itch, scratching
activity can be directly and objectively measured. Furthermore, the relevance of measuring scratching is supported
by finding a significant 24-hour rhythm of this activity in
patients with the pruritus of cholestasis,24 a finding which
suggests that scratching activity in such patients is under
central control and is a direct consequence of the pathophysiological process responsible for the pruritus of cholestasis.
In contrast to this study, previous studies of patients
with the pruritus of cholestasis, in which both assessments
of a VAS and measurements of scratching activity were
made,15,24–26 were not designed primarily to study the relationship between these two variables but to evaluate the efficacy of either intravenously administered naloxone15,24 or
orally administered nalmefene25,26 in ameliorating pruritus.
Accordingly, the relationship between VAS data and measurements of scratching activity was not a primary endpoint in
these previous studies. It follows that that their design did
not enable the relationship between VAS data and measurements of scratching activity to be rigorously evaluated; and,
hence, the need for a more definitive study in which this relationship was itself the primary endpoint was not precluded.
The current study was designed to fulfil this objective and,
consequently, its findings are not directly comparable to
those in any of the previous studies.15,24–26
Although it has long been claimed that itching correlates
strongly with scratching activity,25 this study indicates that
the intensity of the perception of itch, as assessed by a VAS,
does not correlate with an objective quantitative index of
scratching activity in patients with pruritus due to primary
biliary cholangitis. Thus, a VAS, as applied in this study did
not provide a reliable assessment of the magnitude of the
pathophysiological process that is responsible for inducing
scratching activity in our study population (women). Accordingly, the results of this study do not provide support for the
use of a VAS as an endpoint in clinical trials of potential therapies for the pruritus of cholestasis.
Notwithstanding its manifest limitations, VAS has been
popular as an endpoint in this context,7–13 presumably
because it is so easy to apply in clinical studies and investigators may not have been familiar with, or prepared to develop,
any more appropriate alternative. It would appear that the
measurement of scratching activity is such an alternative,
and that a strong case can be made for including measurements of scratching activity as an endpoint in future clinical
trials designed to determine the efficacy of potential therapies
for the pruritus of cholestasis. Failure to include measurements of scratching activity in the design of such studies on
the grounds of the complexity, impracticality or expense of
a scratching activity monitoring system cannot be justified.
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In the case of the monitor used in this study,14 its simplicity
would readily be confirmed by any bioengineer shown its
block diagram (Fig. 2), it is easy to apply and well-tolerated
by patients, and its components are either cheap, such as
piezofilm, or readily available, such as personal computers.
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